Allt inom Other Corporate Information

As communicated in a press release on September 21, 2023, the Board of Directors of Nanexa AB decided, as a result of the announced rights issue, to change the date of the interim report for the period January-September 2023 to November 20, 2023. With this press release, preliminary financial key information for the current period is reported.

Nanexa AB today announces that the phase I study NEX-20-01 has been completed with the last follow-up visits for the last of the three dose levels studied. Nanexa has previously communicated positive results from the pharmacokinetic evaluation and has now also completed the collection of safety and tolerability data that also supports the further development of the project.